168 related articles for article (PubMed ID: 35255180)
1. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.
Qi W; Bai Y; Wang Y; Liu L; Zhang Y; Yu Y; Chen H
APMIS; 2022 Jul; 130(7):371-382. PubMed ID: 35255180
[TBL] [Abstract][Full Text] [Related]
2. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
[TBL] [Abstract][Full Text] [Related]
3. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.
Pan Y; Zhu Q; Hong T; Cheng J; Tang X
Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
5. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
Jin W; Wang G; Dong M; Wang X
Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
[TBL] [Abstract][Full Text] [Related]
6. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
8. Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
Zhang Q; Zhu B; Yang H; Li F; Qu Y; Lu L; Zhang Q
J Gene Med; 2024 Mar; 26(3):e3680. PubMed ID: 38448368
[TBL] [Abstract][Full Text] [Related]
9. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
[TBL] [Abstract][Full Text] [Related]
10. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
[TBL] [Abstract][Full Text] [Related]
11. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
[No Abstract] [Full Text] [Related]
12. Type-1 Na
Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY
Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263
[TBL] [Abstract][Full Text] [Related]
13. Comprehensively prognostic and immunological analysis of VRK Serine/Threonine Kinase 1 in pan-cancer and identification in hepatocellular carcinoma.
Chen D; Zhou W; Chen J; Wang J
Aging (Albany NY); 2023 Dec; 15(24):15504-15524. PubMed ID: 38157278
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.
Liu C; Qu Z; Zhao H; Wang P; Zhan C; Zhang Y
BMC Bioinformatics; 2023 May; 24(1):192. PubMed ID: 37170221
[TBL] [Abstract][Full Text] [Related]
15. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma.
Qiu MJ; Zhang L; Chen YB; Zhu LS; Zhang B; Li QT; Yang SL; Xiong ZF
Int J Biochem Cell Biol; 2021 Aug; 137():106037. PubMed ID: 34217812
[TBL] [Abstract][Full Text] [Related]
16. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
17. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
[TBL] [Abstract][Full Text] [Related]
18. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value and Immunological Role of KIFC1 in Hepatocellular Carcinoma.
Li D; Yu T; Han J; Xu X; Wu J; Song W; Liu G; Zhu H; Zeng Z
Front Mol Biosci; 2021; 8():799651. PubMed ID: 35111813
[TBL] [Abstract][Full Text] [Related]
20. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
